Contents lists available at ScienceDirect





# Phytochemistry Letters

#### journal homepage: www.elsevier.com/locate/phytol

# A new secoiridoid glycoside and a new sesquiterpenoid glycoside from *Valeriana jatamansi* with neuroprotective activity



Yu-Zhu Tan<sup>a,b</sup>, Yan Yong<sup>a,b</sup>, Yan-Hong Dong<sup>a,b</sup>, Ru-Jing Wang<sup>a,b</sup>, Hong-Xiang Li<sup>b</sup>, Hai Zhang<sup>b</sup>, Da-Le Guo<sup>a,b</sup>, Shi-Jin Zhang<sup>b</sup>, Xiao-Ping Dong<sup>b,\*</sup>, Xiao-Fang Xie<sup>a,b,\*\*</sup>

<sup>a</sup> State Key Laboratory Breeding Base of Systematic Research Development and Utilization of Chinese Medicine Resources, Sichuan Province and Ministry of Science and Technology, Chengdu 611137, China

<sup>b</sup> Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China

#### ARTICLE INFO

Article history: Received 4 May 2016 Received in revised form 20 June 2016 Accepted 6 July 2016 Available online xxx

Keywords: Valeriana jatamansi Secoiridoid glycoside Sesquiterpenoid glycoside Neuroprotective activity

### 1. Introduction

*Valeriana jatamansi* Jones belongs to the family Caprifoliaceae, an annual herb distributed widely in the southwest of China and India, which is well known as traditional Chinese medicine with tranquilizing hypnotic, nervous disorders, epilepsy, insanity, snake poisoning and skin diseases (Ming et al., 1997; Mathela et al., 2005; Fernandez et al., 2004). Its root, as an important substitute of European V. officinalis, has been used to treat nervous disorders (Mathela et al., 2005; Fernandez et al., 2004). Previous chemical investigation of V. jatamansi revealed the presence of iriodoids, sesquiterpenoids, essential oil, flavone glycosides and lignans (Ming et al., 1997; Tang et al., 2003; Verma et al., 2011; Lin et al., 2010).

In the course of our continual search for bioactive natural products on nervous systems from *Valeriana* genus, eleven compounds were isolated from the roots of *Valeriana jatamansi* including a new secoiridoid glycoside, isopatrinioside (1) and a new sesquiterpenoid glycoside, valeriananoid F (2), together with

ABSTRACT

A new secoiridoid glycoside, isopatrinioside (1) and a new sesquiterpenoid glycoside, valeriananoid F (2), together with nine known compounds, were isolated from the roots of *Valeriana jatamansi*. Their structures were elucidated on the basis of spectroscopic analysis. Compound 1 was an unusual monocyclic iridoid glycoside ring-opened between C-1 and C-2 produced by the cleavage of the pyran ring. Of the eleven isolates, compounds 1 and 4 exhibited moderate neuroprotective effects against  $CoCl_2$ -induced neuronal cell death in PC12 cells.

© 2016 Phytochemical Society of Europe. Published by Elsevier Ltd. All rights reserved.

nine known compounds. Isopatrinioside (**1**) is a monocyclic iridoid glycoside with pyran ring-opened between C-1 and C-2. To the best of our knowledge, the report about this type monocyclic iridoid from natural sources is still very rare (Wysokinska and Skrzypek, 1992; Dinda et al., 2007, 2009, 2011). Isopatrinioside(**1**) is so far another positional isomer of patrinioside isolated from *valeriana* (Kouno et al., 1995). Valeriananoid F(**2**) is one of the valeriananoid analogues which have been isolated from *V. jatamansi* (Ming et al., 1997; Dong et al., 2015). In this paper, we describe the isolation, structural elucidation of two new compounds and neuroprotective effects of the eleven compounds.

#### 2. Results and discussion

Compound **1** was obtained as an amorphous powder. The IR spectrum showed typical absorption bands for hydroxy (3400 cm<sup>-1</sup>), ester carbonyl (1713 cm<sup>-1</sup>), and glycosyl (1077, 1047 cm<sup>-1</sup>). The molecular formula was determined to be C<sub>21</sub>H<sub>36</sub>O<sub>10</sub> on the basis of the HRESIMS ([M+Na]<sup>+</sup> at *m/z* 471.2204, calcd. for 471.2206) with 4 degrees of unsaturation. The <sup>1</sup>H NMR (Table 1), DEPT combinated with HSQC spectra of **1** showed a doublet methyl signals at  $\delta_c$  22.8 and  $\delta_H$  0.96, methylene carbon signals ( $\delta_c$  45.3), a methine ( $\delta_c$  26.9), and a carbonyl carbon signal at  $\delta_c$  174.4, indicating an isovaleryloxyl ester moiety[ $\delta_H$  0.96 (6H, d, *J* = 6.6 Hz), 2.05 (1H, m), 2.16 (2H, m);  $\delta_c$  174.4, 45.3, 26.9, 22.8], the presence of which was confirmed by correlations in the

http://dx.doi.org/10.1016/j.phytol.2016.07.020

1874-3900/© 2016 Phytochemical Society of Europe. Published by Elsevier Ltd. All rights reserved.

<sup>\*</sup> Corresponding author at: Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.

<sup>\*\*</sup> Corresponding author at: State Key Laboratory Breeding Base of Systematic Research Development and Utilization of Chinese Medicine Resources, Sichuan Province and Ministry of Science and Technology, Chengdu 611137, China.

*E-mail addresses*: dongxiaoping11@126.com (X.-P. Dong), xxf14544@163.com (X.-F. Xie).

## Table 1

 $^1\mathrm{H}$  and  $^{13}\mathrm{C}$  NMR Data (600 and 150 MHz, resp., MeOD- $d_4)$  of 1 and 2 with J values (Hz) in parentheses.

NO.	1		2	
	$\delta_{H}$	$\delta_{C}$	$\delta_{H}$	$\delta_{C}$
1a	4.02 dd (9.6,4.0)	68.0	2.05 dd (14.0,7.6)	37.8
1b	3.50 dd (9.6,8.6)	-	1.60 dd (14.0,6.7)	-
2	_	-	3.96 ddd (7.6,6.7,1.2)	80.4
3a	5.28 d (1.1)	110.2	1.48 t (5.9)	46.0
3b	4.98 bs	-	-	-
4	_	150.7	-	40.0
5	2.97 br q (9.1)	40.2	-	76.6
6a	2.12 ddd (14.5,6.8,1.9)	37.1	1.73 dd (14.3,5.2)	32.8
6b	1.72 ddd (14.5,8.6,3.6)	-	1.54 m	-
7a	4.49 dd (6.8,3.6)	76.7	1.52 m	29.6
7b	_	-	1.38 m	-
8	_	93.1	1.96 m	29.0
9	2.57 td (8.6,4.0)	51.4	1.36 m	44.3
10	1.6 s	19.2	-	41.5
11a	4.10 br d (14.5)	66.7	1.55 m	25.0
11b	4.00 br d (14.5)	-	1.32 m	-
12	_	-	0.81 d (6.7)	19.3
13	_	-	1.09 s	25.7
14	-	-	1.17 s	28.9
15	_	-	0.89 s	21.0
Glc-1	4.13 d (7.8)	104.6	4.33 d (7.8)	103.3
Glc-2	3.13 dd (8.8,7.9)	75.2	3.15 dd (8.8,7.9)	75.3
Glc-3	3.33 br t (8.8)	78.1	3.35 br t (8.8)	77.8
Glc-4	3.27 br t (9.5)	71.6	3.29 m	71.8
Glc-5	3.23 m	77.8	3.24 m	76.6
Glc-6a	3.85 dd (11.9,2.3)	62.7	3.86 dd (11.9,2.3)	62.9
Glc-6b	3.66 dd (11.9,5.6)	-	3.67 dd (11.9,5.6)	-
1′	_	174.4	-	-
2′	2.16 m	45.3	-	-
3′	2.05 m	26.9	-	-
4′	0.96 d (6.6)	22.8	-	-
5′	0.96 d (6.6)	22.8	-	-

<sup>1</sup>H-<sup>1</sup>H COSY and HSQC spectrum. In addition, the presence of a  $\beta$ -glycosyl moiety was established by an anomeric proton [ $\delta_{\rm H}$  4.13 (1H, d, *J* = 7.8 Hz)] and partially overlapped signals attributed to oxymethylene and oxymethine protons between  $\delta_{\rm H}$  3.13 and 3.85. Acid hydrolysis afforded D-glucose as the sole sugar, identified by TLC comparison and the positive optical rotation  $[a]_D^{20} + 47.0^{\circ}$  (Gan et al., 2008; Hudson and Dale, 1917). Five of the remaining 10 carbon signals were ascribable to a methyl ( $\delta_{\rm C}$  19.2), *exo*-methylene ( $\delta_{\rm C}$  150.7 and 110.2), and two oxy-methylene ( $\delta_{\rm C}$  66.7 and 68.0).

The connectivities of the proton coupling sequence for the C-1-C-9-C-5-C-6-C-7 fragment in an iridoid skeleton were observed in the <sup>1</sup>H-<sup>1</sup>H COSY spectrum (Fig. 1). The absence of HMBC correlations between H-3 ( $\delta_H$  5.28 and 4.98) and C-1 ( $\delta_C$  68.0) and/or between H-1 ( $\delta_H$  4.02 and 3.50) and C-3 ( $\delta_C$  110.2) showed

that **1** was a monocyclic iridoid ring-opened. <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data showed the compound gross structure was closely similar to jatamanin J except for the absence of one hexose and isovaleryl moiety (Lin et al., 2010). Detailed analysis of 2D NMR data verified the location of the substitutents. The HMBC correlations (Fig. 1) between the Glc anomeric proton at  $\delta_{\rm H}$  4.13 (1H, d, J=7.8Hz) and C-1 ( $\delta_{\rm C}$  68.0) indicated that the glucose moiety was linked to C-1 ( $\delta_{\rm C}$  68.0) of the aglycone. In the HMBC spectrum (Fig. 1), the position of the isovaleryloxyl ester group was determined as C-8 ( $\delta_{C}$  93.1) on the basis of weak correlation of H-10 ( $\delta_{\rm H}$  1.6) and the ester carbonyl of the isovaleroxyl moiety. The stereo-structure was examined by a NOESY experiment. The NOESY correlations of H-9 ( $\delta_{\rm H}$  2.57) with H-5 ( $\delta_{\rm H}$  2.97) and H-10 ( $\delta_{\rm H}$  1.6), H-7 ( $\delta_H$  4.49) with H-6 $\alpha$  ( $\delta_H$  2.12), H-5 ( $\delta_H$  2.97) with H-6 $\beta$  ( $\delta_H$ 1.72) showed that the H-5 ( $\delta_{\rm H}$  2.97) and H-9 ( $\delta_{\rm H}$  2.57) possess a *cis*configuration and indicated 7 $\beta$ -OH, 8 $\alpha$ -isovaleroxyl groups. Comparisions of NOESY NMR data for **1** with those from jatamanin J allowed the relative configurations at C-5 ( $\delta_{\rm C}$  40.2), C-7 ( $\delta_{\rm C}$  76.7), C-8 ( $\delta_{\rm C}$  93.1), and C-9 ( $\delta_{\rm C}$  51.4) to be identically assigned (Lin et al., 2010). The above data strongly suggested that 1 is a position isomer of patrinioside with an isovaleroxyl group at C-8 ( $\delta_{C}$  93.1) and sugar moiety at C-1 ( $\delta_{C}$  68.0). Thus, the structure of **1** was established as 8-O-isovaleroxyl-1-O-β-D-glucopyranosyl jatamanin I and named isopatrinioside.

Compound 2 was obtained as a white, amorphous powder. 2 had the molecular formula  $C_{21}H_{36}O_7$ , which was determined by HRESIMS ( $[M + Na]^+$  at m/z 423.2352, calcd. for 423.2359), requiring 4 unsaturation. The IR spectrum of 2 displayed the presence of the hydroxyl  $(3414 \text{ cm}^{-1})$  and glycosyl  $(1074,1045 \text{ cm}^{-1})$ . The <sup>1</sup>H NMR spectrum (Table 1) of **2** exhibited four methyls  $[\delta_H 0.81 (3H, d, J = 6.7 Hz), 1.17 (3H, s), 1.09 (3H, s), 0.89$ (3H, s)], and anomeric proton signal of  $\beta$ -glycosyl group at  $\delta_H$  4.33 (1H, d, I = 7.8 Hz), which gave correlation in the HMQC spectrum at  $\delta_{\rm C}$  103.3. The <sup>13</sup>C NMR (Table 1) and DEPT spectroscopic data, in combination with HMQC spectrum, revealed the existence of one tricyclic sesquiterpenoid skeleton, including four methyls [ $\delta_{\rm H}$  1.17  $(1H, s), 1.09 (1H, s), 0.89 (1H, s), 0.81 (1H, d, J = 6.7 Hz); \delta_{C} 28.9, 25.7,$ 21.0, 19.3]; four methylenes [ $\delta_{\rm H}$  2.05 (1H, dd, J = 14.0, 7.6 Hz), 1.60 (1H, dd, J = 14.0, 6.7 Hz), 1.73 (1H, dd, J = 14.3, 5.2 Hz), 1.54 (1H,m), 1.52 (1H,m), 1.38 (1H,m), 1.55 (1H, m), 1.32 (1H, m); δ<sub>C</sub> 37.8, 32.8, 29.6, 25.0], four methines [ $\delta_{\rm H}$  3.96 (1H, ddd, J = 7.6, 6.7, 1.2 Hz), 1.48  $(1H, t, J = 5.9 \text{ Hz}), 1.36 (1H,m), 1.96 (1H,m); \delta_{C} 80.4, 46.0, 44.3, 29.0$ as well as three quaternary carbons [ $\delta_{c}$  40.0, 41.5, 76.6], which according to remaining three unsaturated degree. A careful comparison of the NMR data of 2 with those of the known compound valeriananoid B (Mathela et al., 2005) indicated that they were structural analogues. The only difference was absence the  $\beta$ -p-glucose moiety in valeriananoid B. The position of  $\beta$ -pglucose at C-2 ( $\delta_{C}$  80.4) was confirmed based on the HMBC



Fig. 1. Key <sup>1</sup>H, <sup>1</sup>H COSY, HMBC and NOSEY correlations of compound 1 and 2.

correlation (Fig. 1) from anomeric proton  $\delta_H$  4.33 (1H, d, *J* = 7.8 Hz) to C-2 ( $\delta_C$  80.4). A detailed analysis of HMQC, HMBC and <sup>1</sup>H-<sup>1</sup>H COSY spectrum (Fig. 1) supported the assignment of all protons and carbon signals. The relative configuration of **2** was established by the NOESY experiment. The NOESY correlations of H-1 $\alpha$  ( $\delta_H$  2.05) with H-3 ( $\delta_H$  1.48), H-15 ( $\delta_H$  0.89) with H-3 ( $\delta_H$  1.48), H-8 ( $\delta_H$  1.96) with H-15 ( $\delta_H$  0.89) and H-14 ( $\delta_H$  1.17) with H-1 $\alpha$  ( $\delta_H$  2.05). The relative configuration of **2** was the same as that of valeriananoid B and detailed comparison of the <sup>1</sup>H NMR coupling constants of **2** was defined and named as valeriananoid F.

In addition to the two new compounds **1** and **2**, the known iridoids and sesquiterpenoid were identified by comparison of spectroscopic data with those reported in the literature as 8-methoxy-3-methoxy-10-methylene-2,9-dioxatricyclo[ $4.3.1.0^{3,7}$ ] decan-4-ol (**3**) (Inouye et al., 1974), vibutinal (**4**) (Liu et al., 2010), baldrinal (**5**) (Chen et al., 2005), 11-ethoxyviburtinal (**6**) (Boros and Stermitz, 1991), jatamanvaltrate E (**7**) (Lin et al., 2009), jatamanvaltrate A (**8**) (Lin et al., 2009), jatamanvaltrate F (**9**) (Lin et al., 2009), valeriotetrate C (**10**) (Lin et al., 2010), chlorovaltrate A (**11**) (Lin et al., 2013).

The neuroprotective effects of the compounds against CoCl<sub>2</sub>induced neuronal cell death in PC12 cells were investigated by an established CCK-8 assay. At the concentrations of 0.1  $\mu$ M, 1  $\mu$ M, 10  $\mu$ M, compound **1** and **4** showed potent neuroprotective effects. Compound **1** increased the cell viability from 56.1% to 60.9%, 63.4% and 65.4%, respectively. For compound **4**, the weak neuroprotective activities were exhibited with the viability by 60.4% only with the concentrations of 10  $\mu$ M. However, the other compounds were inactive even at the high concentrations of 10  $\mu$ M. CCK-8 assay indicated that all of the compounds had no significant cytotoxicity to the PC12 cells at their effective concentration required for neuroprotective effects (data not shown).

In the course of our survey on pharmacologically active substances in Chinese herb medcine, much attention has been paid to the occurrence of compounds with neuroprotective effects, since these compounds are expected to be potentially useful for the treatment and prevention of Parkinson's disease (PD). During our search for new types of natural products possessing neuroprotective activities, we investigated the chemical constituents of the roots of V. jatamansi, of which the ethylacetate fractions showed moderate neuroprotective effects. By bioactivity-guided isolation, we isolated and identified a new secoiridoid glycoside (1) and a new sesquiterpenoid glycoside (2) and nine known (3-11) compounds successfully from the roots of V. jatamansi. This study discovered secoiridoid and sesquiterpenoid glycoside from Valeriana and first reported the activity of these compounds against PC12 cell damage. It can be seen that secoiridoid glycoside was bioactive component in V. jatamansi, which has been used as neurological disorder drug for thousands of years in East Asia. Of course, the neuroprotective effect of the secoiridoid aglycone is also worth of our concern in the further research.

#### 3. Experimental

#### 3.1. General experimental procedures

NMR measurements were performed on a Bruker-AVII-600 spectrometer. HRESIMS were obtained using Waters Synapt G<sub>2</sub>HDMS. IR spectra were measured by PerkinElmer one FT-IR spectrometer (KBr). UV spectra were obtained on a Shimadzu UV-260 spectrophotometer. Optical rotations were measured with Anton Paar MCP 200. Preparative HPLC was performed on Shimadazu LC-10AT instrument with an SPD-10AVP detector and a YMC-Pack ODS-A column (250 mm  $\times$  10 mm, 5  $\mu$ m).

Preparative TLC was conducted with glass plates precoated silica gel  $GF_{254}$  (Yantai). TLC was carried out with  $GF_{254}$  plates (Qingdao Marine Chemical Factory). Spots were visualized by spraying with 10%  $H_2SO_4$  in 95% EtOH followed by heating. Column chromatography (CC) was performed with silica gel and Sephadex LH-20. All the solvent used were of analytical grade.

#### 3.2. Plant material

The root of *Valeriana jatamansi* Jones was collected in June of 2014 from the medicinal herbs market in Chengdu, Sichuan Province, China. The medical material identity was verified by Prof. Min Li (Chengdu University of TCM, Sichuan, China). A voucher specimen (ZZX-1407) was deposited at the School of Pharmacy, Chengdu University of TCM, Chengdu, China.

#### 3.3. Extraction, isolation and characterization of compounds

The air-dried roots of Valeriana jatamansi Jones (5 kg), was powdered and exhaustively extracted using by percolating with 75% EtOH ( $3 \times 30$  L). The combined extract was concentrated under reduced pressure to dryness. The residue was suspended in water (2L) and then the successively partitioned with Petroleum Ether  $(3 \times 2L)$ , EtOAc  $(3 \times 2L)$  and *n*-BuOH  $(3 \times 2L)$ . The EtOAc extract (170 g) was subjected to CC over silica gel and eluted with a gradient of CHCl<sub>3</sub>-MeOH [95:5; 90:10; 85:15; 80:20; 75:25; 70:30; 60:40; 50:50; MeOH] to afford nine fractions A-I. Fraction D (3g) and E (4 g) were separated by MHPLC ( $3.6 \text{ cm} \times 46 \text{ cm}$ , ODS, 10 mL/min, 6 h), eluted with 40%, 50%, 60%, 70%, 80%, 90%, 100% MeOH-H<sub>2</sub>O to afford about 7 subfractions respectively. The fraction D<sub>4</sub> (847 mg) was chromatographed over Sephadex LH-20 eluted with MeOH as mobile phase to give three subfractions. Successive separation of the D<sub>4-2</sub> (85 mg) by preparative TLC with CHCl<sub>3</sub>-MeOH (4:1, v/v) to yield 1 (11.5 mg). The subfraction  $D_{4-3}$  (127 mg) was separated by preparative TLC with Pe-EtOAc (15:1, v/v) to yield 4 (15.4 mg) and 5 (10.7 mg). Fraction  $D_5$  (215 mg)was further purified by CC over Sephadex LH-20 eluted with MeOH-H<sub>2</sub>O (9:1, v/ v) as mobile phase to give five subfractions. The subfraction  $D_{5-2}$ (58 mg) was purified by preparative TLC with petroleum ether-EtOAc (20:1, v/v) to **7** (11.2 mg). The Fraction D<sub>5-3</sub> (48 mg)was purified by preparative HPLC using 75% MeOH-H<sub>2</sub>O (3 mL/min) as mobile phase to afford 2 (8.8 mg) and 6 (6.7 mg). At last, Fraction D<sub>5-4</sub> (45 mg) was purified by preparative HPLC using 70% MeOH- $H_2O(3 \text{ mL/min})$  as mobile phase to afford **10** (10.5 mg), **11**(8.5 mg). Fraction E<sub>3</sub> (86 mg) was purified by preparative HPLC using 75% MeOH-H<sub>2</sub>O (3 mL/min) as mobile phase to yield 3 (7.5 mg) and 8 (10.5 mg). The fraction E<sub>4</sub> (118 mg) was chromatographed over Sephadex LH-20 eluted with MeOH as mobile phase to give four subfractions. The subfraction  $E_{4-3}$  (50 mg) was purified by preparative TLC with petroleum ether-EtOAc (10:1,v/v) to yield 9 (12.5 mg).

#### 3.3.1. Isopatrinioside (1)

Amorphous powder;  $[a]_D^{20} - 15.6^{\circ}$  (c = 0.02, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\varepsilon$ ): 206 (3.87), 220 (3.77); IR (KBr)  $\nu_{max}$  cm<sup>-1</sup>: 3400, 2958, 1713, 1605, 1077, 1047; HRESIMS m/z: 471.2204 [M+Na]<sup>+</sup> (calcd for C<sub>21</sub> H<sub>36</sub> O<sub>10</sub>Na 471.2206); <sup>1</sup>H and <sup>13</sup>C NMR data see Table 1.

#### 3.3.2. Valeriananoid F(2)

Amorphous powder;  $[a]_D^{20} - 18.6^{\circ}$  (c = 0.05, MeOH); UV (MeOH)  $\lambda_{max}$  (log $\epsilon$ ): 209 (3.27), 220 (3.14), 228 (3.16); IR (KBr)  $\nu_{max}$  cm<sup>-1</sup>: 3414, 2926, 2870, 1574, 1416, 1074, 1045; HRESIMS *m*/*z*: 423.2352 [M+Na]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>36</sub>O<sub>7</sub>Na 423.2359); <sup>1</sup>H and <sup>13</sup>C NMR data see Table 1.

#### 3.4. Acid hydrolysis

A solution of each compound (2.0 mg) in 2 N aqueous HCl (5 mL) was refluxed for 3 h. The residue was partitioned between H<sub>2</sub>O (10 mL) and EtOAc ( $3 \times 5$  mL). The aqueous phase was evaporated under reduced pressure to give the sugar residue which could be identified as D-glucose by the sign of its optical rotation ( $[a]_D^{20} + 47.0^\circ$ , c 0.05, H<sub>2</sub>O). Similarly, compound **2** was hydrolyzed to afford the same sugar.

#### 3.5. Neuroprotective effect assay

Rat pheochromocytoma cell line (PC12) were cultured in 96well plates with DMEM supplemented with 10% (v/v) inactivated fetal bovine serum, and 100 U/mL penicillin/streptomycin. The cells were maintained at 37 °C in 5% CO<sub>2</sub> and 95% humidified air incubator. The cells were subcultured every three days. At 24 h before experiments, the medium was substituted by serumdeprived medium. Cells were pre-treated for 2 h with various concentrations (0.01, 0.1, 1.0, 10  $\mu$ M) of compounds before incubation in a medium containing 300  $\mu$ M CoCl<sub>2</sub>. After incubation for 4 h, 10  $\mu$ L CCK-8 solution was added. Absorbance was measured at 450 nm using a microplate reader.

#### Acknowledgments

Financial support from the project for National Science Foundation for Fostering Talents in Basic Research of the National Natural Science Foundation of China fund (grant No. J13100340-11), the key fund project for Education Department of Sichuan (grant No. 15ZA0093), the youth science and technology innovative research team fund project of Sichuan (grant No. 2016TD0006) and the project for administration of Traditional Chinese Medicine (grant No. 2016Q049).

#### Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j. phytol.2016.07.020.

#### References

- Boros, C.A., Stermitz, F.R., 1991. Iridoids. an updated review part II. J. Nat.Prod 54, 1173–1246.
- Chen, Y.G., Yu, L.L., Huang, R., Lv, Y.P., Gui, S.H., 2005. 11-Methoxyviburtinal, A new iridoid from Valeriana jatamansi. Arch. Pharm. Res. 28, 1161–1163.
- Dinda, B., Debnath, S., Harigaya, Y., 2007. Naturally occurring iridoids. A review, part 1. Chem. Pharm. Bull. 55, 159–222.
- Dinda, B., Chowdhury, D.R., Mohanta, B.C., 2009. Naturally occurring iridoids, secoiridoids and their bioactivity. An updated review, part 3. Chem. Pharm. Bull. 57, 765–796.
- Dinda, B., Debnath, S., Banik, R., 2011. Naturally occurring iridoids and secoiridoids. An updated review, part 4. Chem. Pharm. Bull. 59, 803–833.
- Dong, F.W., Yang, L., Wu, Z.K., Gao, W., Zi, C.T., Yang, D., Luo, H.R., Zhou, J., Hu, J.M., 2015. Iridoids and sesquiterpenoids from the roots of *Valeriana jatamansi* Jones. Fitoterapia 102, 27–34.
- Fernandez, S., Wasowski, C., Paladini, A.C., Marder, M., 2004. Sedative and sleepenhancing properties of linarin: a flavonoid-isolated from Valeriana officinalis. Pharmacol. Biochem. Behav. 77, 399–404.
- Gan, M.L., Zhang, Y.L., Lin, S., Liu, M.T., Song, W.X., Zi, J.C., Yang, Y.C., Fan, X.N., Shi, J.G., Hu, J.F., Sun, J.D., Chen, N.H., 2008. Glycosides from the root of *lodes cirrhosa*. J. Nat.Prod. 71, 647–654.
- Hudson, C.S., Dale, J.K., 1917. Studies on the forms of D-glucose and their mutarotation. J. Am. Chem. Soc. 39, 320–328.
- Inouye, H., Ueda, S., Uesato, S., Shingu, T., 1974. Die absolute konfiguration von valerosidatum und von didrovaltratum. Tetrahedron 30, 2317–2325.
- Kouno, I., Koyama, I., Jiang, Z.H., Tanaka, T., Yang, D.M., 1995. Patrinioside, an eaterified monocyclic irodoid glucoside from *Patrinia scabra*. Phytochemistry 40, 1567–1568.
- Lin, S., Shen, Y.H., Li, H.L., Yang, X.W., Chen, T., Lu, L.H., Huang, Z.S., Liu, R.H., Xu, X.K., Zhang, W.D., Wang, H., 2009. Acylated iridoids with cytotoxicity from Valeriana jatamansi. J. Nat. Prod. 72, 650–655.
- Lin, S., Chen, T., Niu, X.H., Shen, Y.H., Li, H.L., Shan, L., Liu, R.H., Xu, X.K., Zhang, W.D., Wang, H., 2010. Iridoids and lignans from *Valeriana jatamansi*. J. Nat. Prod. 73, 632–638.
- Lin, S., Zhang, Z.X., Chen, T., Ye, J., Dai, W.X., Shan, L., Su, J., Shen, Y.H., Li, H.L., Liu, R.H., Xu, X.K., Wang, H., Zhang, W.D., 2013. Characterization of chlorinated valepotriates from *Valeriana jatamansi*. Phytochemistry 85, 185–193.
- Liu, F.L., Feng, F., Liu, W.Y., 2010. Chemical constituents of *Patrinia scabra*. Pharm. Clin. Res. 04, 356–359.
- Mathela, C.S., Chanotiya, C.S., Sammal, S.S., Pant, A.K., Pandey, S., 2005. Compositional diversity of terpenoids in the himalayan *Valeriana* Genera. Chem. Biodiv. 2, 1174–1182.
- Ming, D.S., Yu, D.Q., Yang, Y.Y., He, C.M., 1997. The structures of three novel sesquiterpenoids from *Valeriana jatamansi* Jones. Tetrahedron Lett. 38, 5205– 5208.
- Tang, Y.P., Liu, X., Yu, B., 2003. Two new flavone glycosides from Valeriana Jatamansi. J. Asian Nat. Prod. Res. 5, 257–261.
- Verma, R.S., Verma, R.K., Padalia, R.C., Chauhan, A., Singh, A., Singh, H.P., 2011. Chemical diversity in the essential oil of indian valerian (*Valeriana jatamansi* Jones). Chem. Biodivers. 8, 1921–1929.
- Wysokinska, H., Skrzypek, Z., 1992. An iridoid from *Penstemon serrulatus* cultures. Phytochemistry 31, 1235–1237.